Abstract

The aim of this study was to investigate the C-terminal cleavage of (pyr)-apelin-13 in human endothelial cells with respect to the role and subcellular location of prolyl carboxypeptidase (PRCP). Human umbilical vein and aortic endothelial cells, pre-treated with prolyl carboxypeptidase-inhibitor compound 8o and/or angiotensin converting enzyme 2 (ACE2)-inhibitor DX600, were incubated with (pyr)-apelin-13 for different time periods. Cleavage products of (pyr)-apelin-13 in the supernatant were identified by mass spectrometry. The subcellular location of PRCP was examined via immunocytochemistry. In addition, PRCP activity was measured in supernatants and cell lysates of LPS-, TNFα-, and IL-1β-stimulated cells. PRCP cleaved (pyr)-apelin-13 in human umbilical vein and aortic endothelial cells, while ACE2 only contributed to this cleavage in aortic endothelial cells. PRCP was found in endothelial cell lysosomes. Pro-inflammatory stimulation induced the secretion of PRCP in the extracellular environment of endothelial cells, while its intracellular level remained intact. In conclusion, PRCP, observed in endothelial lysosomes, is responsible for the C-terminal cleavage of (pyr)-apelin-13 in human umbilical vein endothelial cells, while in aortic endothelial cells ACE2 also contributes to this cleavage. These results pave the way to further elucidate the relevance of the C-terminal Phe of (pyr)-apelin-13.

Highlights

  • IntroductionProlyl carboxypeptidase (PRCP, angiotensinase C, EC 3.4.16.2) is a serine protease known for its role in the alternative renin-angiotensin system and plasma kallikrein-kinin system [1,2,3]

  • In human umbilical vein endothelial cells (HUVEC), the cleavage is mediated only by PRCP, while in human aortic endothelial cells (HAoEC), angiotensin converting enzyme 2 (ACE2) contributes to this cleavage

  • We confirm that PRCP is found in endothelial lysosomes

Read more

Summary

Introduction

Prolyl carboxypeptidase (PRCP, angiotensinase C, EC 3.4.16.2) is a serine protease known for its role in the alternative renin-angiotensin system and plasma kallikrein-kinin system [1,2,3]. Soon after its discovery as des-Arg9 -bradykinin-, angiotensin II-, and IIIcleaving enzyme, it was clear that PRCP cleaves C-terminal amino acids from peptides with a general structure of R1-Pro-R2 [1,4]. PRCP has been implicated in the pathophysiology of hypertension and inflammation [5,6,7,8,9].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call